Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET
Company Participants
Ian Karp - SVP, IR & Corporate Communications
John Leonard - President, CEO & Director
David Lebwohl - EVP & Chief Medical Officer
Laura Sepp-Lorenzino - EVP & Chief Scientific Officer
Glenn Goddard - EVP, CFO & Treasurer
Conference Call Participants
Swapnil Malekar - Piper Sandler & Co.
Maurice Raycroft - Jefferies
Dae Gon Ha - Stifel, Nicolaus & Company
Salveen Richter - Goldman Sachs Group
Joseph Thome - Cowen and Company
Gena Wang - Barclays Bank
Luca Issi - RBC Capital Markets
Mani Foroohar - SVB Leerink
Yanan Zhu - Wells Fargo Securities
Jay Olson - Oppenheimer
Operator
Good morning. My name is Drew, and I will be your conference operator today, and welcome to the Intellia Therapeutics First Quarter 2022 earnings conference call. [Operator Instructions].
At this time, I would like to turn it over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Ian Karp
Thank you, operator. Good morning, everyone. Welcome to Intellia Therapeutics first quarter 2022 Earnings Call. Earlier this morning, Intellia issued a press release outlining the company's progress this quarter as well as topics for discussion on today's call. This release can be found on the Investors and Media section of Intellia's website at intelliatx.com. This call is being broadcast live, and a replay will be archived on the company's website.
At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements and ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intellia undertakes no duty to update
- Read more current NTLA analysis and news
- View all earnings call transcripts